22 October 2019 : Original article
BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin LymphomaAna Lucia Ron-Magaña12ABCDEF, Omar Eduardo Fernandez-Vargas23CDEF, Esperanza Barrera-Chairez23ADF, Carlos Silvestre Ron-Guerrero4CDF, Ana Jaqueline Bañuelos-Ávila1ABCDEF*
Ann Transplant 2019; 24:584-587
BACKGROUND: High-dose chemotherapy followed by autologous hematopoietic stem cell transplant has proven useful in relapsed or refractory cases of Hodgkin and non-Hodgkin lymphoma. BEAM (carmustine, etoposide, cytarabine, melphalan) is frequently used as a conditioning regimen; however, the high cost and limited availability of BCNU hinders its use in Mexico.
MATERIAL AND METHODS: Between January 2013 and February 2019, refractory or relapsing HL and NHL patients were treated with an autologous HSCT conditioned with cisplatin+dexamethasone as substitution for BCNU in BEAM.
RESULTS: Four HL patients and 6 NHL patients were included; 60% were male, the average age was 34.5±15.2 years, the median follow-up was 19.1 months, and 70% had a complete response after transplant. OS at 12 months was 63% for NHL and 100% for HL. Time to hematological recovery was 17.6±2.8 days; all patients developed grade III/IV neutropenia and thrombocytopenia, and 8 patients had transplant-related infections.
CONCLUSIONS: This retrospective study based on real-world data introduces the option of substituting carmustine with cisplatin+dexamethasone, with a similar response, expected lower cost, and better accessibility in developing nations.
Keywords: Bone Marrow Transplantation, Hodgkin Disease, Lymphoma, Non-Hodgkin, Transplantation Conditioning, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cisplatin, Combined Modality Therapy, Cytarabine, Dexamethasone, Melphalan, Middle Aged, Pilot Projects, Podophyllotoxin, Retrospective Studies, Transplantation, Autologous, young adult
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588